Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 439 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Sclerosis Relapse Clear all

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Alemtuzumab, Interferon beta-1a; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 36
States / cities: Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 31 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Tolebrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Cullman, Alabama • Maitland, Florida • Tampa, Florida + 5 more

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: dimethyl fumarate, tetanus diphtheria toxoids vaccine, 23-valent pneumococcal polysaccharide vaccine, meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent), non-pegylated interferon; Drug · Biological
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 14
States / cities: Gilbert, Arizona • Thornton, Colorado • Fort Lauderdale, Florida + 11 more

Conditions: Multiple Sclerosis
Interventions: BIIB033, Placebo, Avonex; Drug · Other
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 58 Years
Enrollment: 419 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 11
States / cities: Cullman, Alabama • Phoenix, Arizona • Raleigh, California + 8 more

Conditions: Relapsing Multiple Sclerosis
Interventions: natalizumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 11
States / cities: Fullerton, California • Aurora, Colorado • Des Moines, Iowa + 8 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 973 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 5
States / cities: Concord, North Carolina • Davidson, North Carolina • Durham, North Carolina + 2 more

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 2,199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 32
States / cities: Cullman, Alabama • Sun City, Arizona • Tucson, Arizona + 29 more

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Glatiramer Acetate, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 25
States / cities: Cullman, Alabama • Fresno, California • La Jolla, California + 17 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Teriflunomide, Evobrutinib; Drug
Lead sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 38
States / cities: Cullman, Alabama • Scottsdale, Arizona • Tucson, Arizona + 34 more

Conditions: Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis
Interventions: GEMS Plus, GEMS; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 16 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple Sclerosis
Interventions: estriol, Placebo, Norethindrone, Progestin Placebo; Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Albuquerque, New Mexico + 1 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 1,882 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 86
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 74 more

Conditions: Multiple Sclerosis
Interventions: Ofatunumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: San Francisco, California • Aurora, Colorado • Winfield, Illinois + 1 more

Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, Waldenström Macroglobulinemia
Interventions: alvocidib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Observation of Ocrelizumab as Treatment in RRMS Patients; Other
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: alemtuzumab GZ402673; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,062 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 52
States / cities: Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: EHP-101 25 mg OD, EHP-101 25 mg BID, EHP-101 50 mg OD, EHP-101 50 mg BID; Drug
Lead sponsor: Emerald Health Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Cullman, Alabama • Fullerton, California • Port Orange, Florida

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Rocky Mountain MS Research Group, LLC; Other
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Relapsing Multiple Sclerosis
Interventions: peginterferon beta-1a; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,077 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 7
States / cities: Atlanta, Georgia • Lexington, Kentucky • Baltimore, Maryland + 4 more

Conditions: Multiple Sclerosis
Interventions: teriflunomide; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 21 Years to 60 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 3
States / cities: Phoenix, Arizona • Latham, New York • Portland, Oregon

Conditions: Multiple Sclerosis
Interventions: Avonex® monotherapy (6.0 MIU administered i.m. each week); Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo, Avonex®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Search by objective public record fields.

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis

Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies

The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Study of Evobrutinib in Participants With RMS

An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis

Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk

Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies

Long-Term Safety and Efficacy Study of Peginterferon Beta-1a

MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV

Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)